| A349 |
Yeda patent anti-MMP-9 Biosimilar(Anti-MMP9 Reference Antibody)
Featured
|
|
|
| A350 |
TA136 Biosimilar(Anti-MPL / TPOR / CD110 Reference Antibody)
Featured
|
|
|
| A351 |
Copenhagen Rigshospitalet patent anti-uPARAP Biosimilar(Anti-MRC2 / CD280 Reference Antibody)
Featured
|
|
|
| A352 |
Quark patent anti-ENDO 180 Biosimilar（Anti-MRC2 / CD280 Reference Antibody）
Featured
|
|
|
| A353 |
Narnatumab Biosimilar（Anti-MSPR / RON / CD136 Reference Antibody）
Featured
|
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer. |
|
| A354 |
Aveo anti-RON Biosimilar（Anti-MSPR / RON / CD136 Reference Antibody）
Featured
|
|
|
| A355 |
H5B14 Biosimilar（Anti-MSPR / RON / CD136 Reference Antibody）
Featured
|
|
|
| A356 |
Ensituximab Biosimilar（Anti-MU5AC Reference Antibody）
Featured
|
Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer. |
|
| A357 |
Gatipotuzumab Biosimilar（Anti-MUC1 Reference Antibody）
Featured
|
Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC). |
|
| A358 |
Clivatuzumab Biosimilar(Anti-MUC1 Reference Antibody)
Featured
|
Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers. |
|
| A359 |
Oregovomab Biosimilar(Anti-MUC16 Reference Antibody)
Featured
|
|
|
| A360 |
Abagovomab Biosimilar(Anti-MUC16 Reference Antibody)
Featured
|
Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a murine monoclonal anti-idiotypic antibody, against the tumor-associated antigen, CA-125. Abagovomab is generated by a mouse hybridoma, can imitate the human TAA, CA-125. Abagovomab can elicit humoral and cellular immune responses against ovarian cancer (oc). |
|
| A361 |
Sofituzumab Biosimilar(Anti-MUC16 Reference Antibody)
Featured
|
Sofituzumab (MMUC 1206A) is a humanizedized anti-MUC16 recombinant V-kappa antibody. |
|
| A362 |
Forerunner patent anti-Muc 17 Biosimilar(Anti-MUC17 Reference Antibody)
Featured
|
|
|
| A363 |
Argenx patent anti-MuSK Biosimilar(Anti-MUSK Reference Antibody)
Featured
|
|
|
| A364 |
Alt-100 Biosimilar(Anti-NAMPT Reference Antibody)
Featured
|
|
|
| A365 |
Lifastuzumab Biosimilar(Anti-NaPi2b / SLC34A2 Reference Antibody)
Featured
|
Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity. |
|
| A366 |
Upifitamab Biosimilar(Anti-NaPi2b / SLC34A2 Reference Antibody)
Featured
|
Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer. |
|
| A367 |
Lorvotuzumab Biosimilar(Anti-NCAM1 / CD56 Reference Antibody)
Featured
|
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine. |
|
| A368 |
Enfortumab Biosimilar(Anti-Nectin-4 Reference Antibody)
Featured
|
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma. |
|
| A369 |
Tanezumab Biosimilar(Anti-NGF / bNGF Reference Antibody)
Featured
|
Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia. |
|
| A370 |
Fasinumab Biosimilar(Anti-NGF / bNGF Reference Antibody)
Featured
|
Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies. |
|
| A371 |
MEDI-578 Biosimilar(Anti-NGF / bNGF Reference Antibody)
Featured
|
|
|
| A372 |
Fulranumab Biosimilar（Anti-NGF / bNGF Reference Antibody）
Featured
|
Fulranumab is a human IgG2 monoclonal antibody against nerve growth factor (NGF) and can be used for the research of pain. |
|
| A373 |
AS2886401-00 Biosimilar（Anti-NGF / bNGF Reference Antibody ）
Featured
|
|
|
| A374 |
Monalizumab Biosimilar（Anti-NKG2A / CD94 Reference Antibody）
Featured
|
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC). |
|
| A375 |
Tesnatilimab Biosimilar（Anti-NKG2D / CD314 Reference Antibody）
Featured
|
Tesnatilimab is a human IgG4 monoclonal antibody that acts on the immune activating receptor NKG2D and has potential immunomodulatory and anti-inflammatory activity. Tesnatilimab can be used in the study of inflammatory bowel disease (IBD). |
|
| A376 |
Abbott patent anti-NGR Biosimilar（Anti-Nogo Receptor / NgR Reference Antibody）
Featured
|
|
|
| A377 |
Pfizer patent anti-Notch1 Biosimilar（Anti-NOTCH1 Reference Antibody）
Featured
|
|
|
| A378 |
Tarextumab Biosimilar（Anti-NOTCH3 Reference Antibody）
Featured
|
Tarextumab (OMP-59R5) is an anti-Notch2/3 fully human IgG2 monoclonal antibody. Tarextumab shows anti-tumor activity. |
|
